Asian Growth Companies With Strong Insider Confidence November 2025

As Asian markets navigate a landscape marked by economic fluctuations and investor sentiment shifts, the focus on insider confidence in growth companies becomes increasingly relevant. In this article, we explore three Asian growth companies where high insider ownership signals strong belief in their potential, offering insights into what makes these stocks noteworthy amidst current market dynamics.

Top 10 Growth Companies With High Insider Ownership In Asia

Name	Insider Ownership	Earnings Growth
Streamax Technology (SZSE:002970)	32.5%	33.1%
Sineng ElectricLtd (SZSE:300827)	36%	30%
Seers Technology (KOSDAQ:A458870)	33.9%	79.1%
Novoray (SHSE:688300)	23.6%	31.4%
Loadstar Capital K.K (TSE:3482)	31%	23.6%
Laopu Gold (SEHK:6181)	34.8%	34.3%
J&V Energy Technology (TWSE:6869)	17.5%	31.6%
Gold Circuit Electronics (TWSE:2368)	31.4%	31.1%
Fulin Precision (SZSE:300432)	11.6%	55.2%
Ascentage Pharma Group International (SEHK:6855)	12.8%	30.3%

Click here to see the full list of 616 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.

We're going to check out a few of the best picks from our screener tool.

RemeGen (SEHK:9995)

Simply Wall St Growth Rating: ★★★★★★

Overview: RemeGen Co., Ltd. is a biopharmaceutical company that focuses on discovering, developing, producing, and commercializing biological drugs for autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States with a market cap of approximately HK$51.05 billion.

Operations: The company's revenue from its biopharmaceutical research, service, production, and sales segment amounts to CN¥2.23 billion.

Insider Ownership: 12.4%

Revenue Growth Forecast: 27.3% p.a.

RemeGen is poised for significant growth, with revenue projected to increase by 27.3% annually, outpacing the Hong Kong market. Despite recent insider selling and a volatile share price, the company trades at 23.2% below its estimated fair value. RemeGen's innovative drug developments in autoimmune diseases show promise, supported by positive clinical trial results and international recognition, although it remains unprofitable with substantial net losses reported recently.

• Delve into the full analysis future growth report here for a deeper understanding of RemeGen.
• Our valuation report here indicates RemeGen may be overvalued.

Optowide Technologies (SHSE:688195)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Optowide Technologies Co., Ltd. specializes in the research, development, production, and sale of precision optics and fiber components both in China and internationally, with a market cap of CN¥18.97 billion.

Operations: Optowide Technologies Co., Ltd. generates revenue through its expertise in precision optics and fiber components, serving both domestic and international markets.

Insider Ownership: 36.8%

Revenue Growth Forecast: 28.8% p.a.

Optowide Technologies shows strong growth potential with earnings forecasted to increase by 34.29% annually, surpassing the Chinese market's growth rate. Recent earnings reports indicate a rise in revenue to CNY 425.13 million for the nine months ending September 2025, up from CNY 331.85 million a year earlier, reflecting robust business expansion. However, its share price has been highly volatile recently and its Return on Equity is expected to remain low at 13.7% in three years.

• Take a closer look at Optowide Technologies' potential here in our earnings growth report.
• Our valuation report unveils the possibility Optowide Technologies' shares may be trading at a premium.

Shenzhen Newway Photomask Making (SHSE:688401)

Simply Wall St Growth Rating: ★★★★★★

Overview: Shenzhen Newway Photomask Making Co., Ltd is a lithography company focused on the design, development, and production of mask products in China, with a market cap of CN¥9.58 billion.

Operations: The company's revenue primarily comes from its Electronic Components & Parts segment, which generated CN¥1.10 billion.

Insider Ownership: 32.1%

Revenue Growth Forecast: 30.4% p.a.

Shenzhen Newway Photomask Making demonstrates significant growth potential, with earnings projected to rise 35.46% annually and revenue expected to grow by 30.4%, both outpacing the Chinese market's averages. Recent results show a revenue increase to CNY 827 million for the first nine months of 2025, up from CNY 602.57 million last year, indicating strong business momentum. Despite high volatility in its share price, it trades at a substantial discount to estimated fair value.

• Click to explore a detailed breakdown of our findings in Shenzhen Newway Photomask Making's earnings growth report.
• In light of our recent valuation report, it seems possible that Shenzhen Newway Photomask Making is trading behind its estimated value.

Taking Advantage

• Explore the 616 names from our Fast Growing Asian Companies With High Insider Ownership screener here.
• Interested In Other Possibilities? Outshine the giants: these 27 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com